Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikari, Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikari
Abstract
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [A/T/(N)] framework for Alzheimer's disease. However, the blood-based neurodegeneration marker neurofilament light is not specific to Alzheimer's disease while total-tau shows lack of correlation with CSF total-tau. Recent studies suggest that blood total-tau originates principally from peripheral, non-brain sources. We sought to address this challenge by generating an anti-tau antibody that selectively binds brain-derived tau and avoids the peripherally expressed 'big tau' isoform. We applied this antibody to develop an ultrasensitive blood-based assay for brain-derived tau, and validated it in five independent cohorts (n = 609) including a blood-to-autopsy cohort, CSF biomarker-classified cohorts and memory clinic cohorts. In paired samples, serum and CSF brain-derived tau were significantly correlated (rho = 0.85, P < 0.0001), while serum and CSF total-tau were not (rho = 0.23, P = 0.3364). Blood-based brain-derived tau showed equivalent diagnostic performance as CSF total-tau and CSF brain-derived tau to separate biomarker-positive Alzheimer's disease participants from biomarker-negative controls. Furthermore, plasma brain-derived tau accurately distinguished autopsy-confirmed Alzheimer's disease from other neurodegenerative diseases (area under the curve = 86.4%) while neurofilament light did not (area under the curve = 54.3%). These performances were independent of the presence of concomitant pathologies. Plasma brain-derived tau (rho = 0.52-0.67, P = 0.003), but not neurofilament light (rho = -0.14-0.17, P = 0.501), was associated with global and regional amyloid plaque and neurofibrillary tangle counts. These results were further verified in two memory clinic cohorts where serum brain-derived tau differentiated Alzheimer's disease from a range of other neurodegenerative disorders, including frontotemporal lobar degeneration and atypical parkinsonian disorders (area under the curve up to 99.6%). Notably, plasma/serum brain-derived tau correlated with neurofilament light only in Alzheimer's disease but not in the other neurodegenerative diseases. Across cohorts, plasma/serum brain-derived tau was associated with CSF and plasma AT(N) biomarkers and cognitive function. Brain-derived tau is a new blood-based biomarker that outperforms plasma total-tau and, unlike neurofilament light, shows specificity to Alzheimer's disease-type neurodegeneration. Thus, brain-derived tau demonstrates potential to complete the AT(N) scheme in blood, and will be useful to evaluate Alzheimer's disease-dependent neurodegenerative processes for clinical and research purposes.
Keywords: Alzheimer’s disease; neurodegenerative disease; neurofilament light; plasma brain-derived-tau; total-tau.
Conflict of interest statement
M.T. and P.H. are employees of Bioventix Plc. H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave, and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen and Roche. K.B. has served as a consultant or at advisory boards for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics and Siemens Healthineers. H.Z. and K.B. are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. The other authors declare no competing interests.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Figures
References
- Jack CR, Bennett DA, Blennow K, et al. . NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–562.
- Jack CR, Bennett DA, Blennow K, et al. . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539–547.
- Dubois B, Villain N, Frisoni GB, et al. . Clinical diagnosis of Alzheimer’s disease: Recommendations of the international working group. Lancet Neurol. 2021;20:484–496.
- Alzheimer’s Association . 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;16:391–460.
- Ashton NJ, Hye A, Rajkumar AP, et al. . An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. Nat Rev Neurol. 2020;16:265–284.
- Karikari TK, Ashton NJ, Brinkmalm G, et al. . Blood phospho-tau in Alzheimer’s disease: Analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400–418.
- Teunissen CE, Verberk IMW, Thijssen EH, et al. . Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol. 2021;21:66–77.
- Ashton NJ, Leuzy A, Karikari TK, et al. . The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48:2140–2156.
- Sabbagh MN, Hendrix S, Harrison JE. FDA position statement “Early Alzheimer’s disease: Developing drugs for treatment, guidance for industry”. Alzheimers Dement (N Y). 2019;5:13–19.
- Keshavan A, Pannee J, Karikari TK, et al. . Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70. Brain. 2021;144:434–449.
- Janelidze S, Teunissen CE, Zetterberg H, et al. . Head-to-head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease. JAMA Neurol. 2021;78:1375–1382.
- Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249–254.
- Schindler SE, Bollinger JG, Ovod V, et al. . High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647–e1659.
- Karikari TK, Pascoal TA, Ashton NJ, et al. . Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19:422–433.
- Palmqvist S, Janelidze S, Quiroz YT, et al. . Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324:772–781.
- Janelidze S, Mattsson N, Palmqvist S, et al. . Plasma p-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26:379–386.
- Thijssen EH, La Joie R, Wolf A, et al. . Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26:387–397.
- Thijssen EH, Joie RL, Strom A, et al. . Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. Lancet Neurol. 2021;20:739–752.
- Ashton NJ, Pascoal TA, Karikari TK, et al. . Plasma p-tau231: A new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021;141:709–724.
- Mattsson-Carlgren N, Janelidze S, Bateman RJ, et al. . Soluble p-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13:e14022.
- Ashton NJ, Janelidze S, Al Khleifat A, et al. . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12:3400.
- Bridel C, van Wieringen WN, Zetterberg H, et al. . Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: A systematic review and meta-analysis. JAMA Neurol. 2019;17:1035–1048.
- Benedet AL, Leuzy A, Pascoal TA, et al. . Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease. Brain. 2020;143:3793–3804.
- Clark C, Lewczuk P, Kornhuber J, et al. . Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression. Alzheimers Res Ther. 2021;13:65.
- Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease. J Exp Med. 2020;217:e20200861.
- Frank B, Ally M, Brekke B, et al. . Plasma p-tau181 shows stronger network association to Alzheimer’s disease dementia than neurofilament light and total tau. Alzheimers Dement. 2022;18:1523–1536.
- Mattsson N, Zetterberg H, Janelidze S, et al. . Plasma tau in Alzheimer disease. Neurology. 2016;87:1827–1835.
- Müller S, Preische O, Göpfert JC, et al. . Tau plasma levels in subjective cognitive decline: Results from the DELCODE study. Sci Rep. 2017;7:9529.
- Zetterberg H, Wilson D, Andreasson U, et al. . Plasma tau levels in Alzheimer’s disease. Alzheimers Res Ther. 2013;5:9.
- Grothe MJ, Moscoso A, Ashton NJ, et al. . Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021;97:e1229–e1242.
- Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol. 2006;5:228–234.
- Skillbäck T, Farahmand BY, Rosén C, et al. . Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain. 2015;138:2716–2731.
- Sjögren M, Davidsson P, Tullberg M, et al. . Both total and phosphorylated tau are increased in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70:624–630.
- Thomann PA, Kaiser E, Schönknecht P, Pantel J, Essig M, Schröder J. Association of total tau and phosphorylated tau 181 protein levels in cerebrospinal fluid with cerebral atrophy in mild cognitive impairment and Alzheimer disease. J Psychiatry Neurosci. 2009;34:136–142.
- Dugger BN, Whiteside CM, Maarouf CL, et al. . The presence of select tau species in human peripheral tissues and their relation to Alzheimer’s disease. J Alzheimers Dis. 2016;51:345–356.
- Fischer I, Baas PW. Resurrecting the mysteries of big tau. Trends Neurosci. 2020;43:493–504.
- Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez J. Primary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci U S A. 1992;89:4378–4381.
- Georgieff IS, Liem RK, Mellado W, Nunez J, Shelanski ML. High molecular weight tau: Preferential localization in the peripheral nervous system. J Cell Sci. 1991;100(Pt 1):55–60.
- Mielke MM, Hagen CE, Wennberg AMV, et al. . Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic study on aging. JAMA Neurol. 2017;74:1073–1080.
- Neselius S, Zetterberg H, Blennow K, et al. . Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj. 2013;27:425–433.
- Olivera A, Lejbman N, Jeromin A, et al. . Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol. 2015;72:1109–1116.
- Pase MP, Himali JJ, Aparicio HJ, et al. . Plasma total-tau as a biomarker of stroke risk in the community. Ann Neurol. 2019;86:463–467.
- Rubenstein R, Chang B, Yue JK, et al. . Comparing plasma phospho tau, total tau, and phospho tau–total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 2017;74:1063–1072.
- Shahim P, Tegner Y, Wilson DH, et al. . Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 2014;71:684–692.
- Osborne J, Harrison P, Butcher R, Ebsworth N, Tan K. Novel super-high affinity sheep monoclonal antibodies against CEA bind colon and lung adenocarcinoma. Hybridoma. 1999;18:183–191.
- Karikari TK, Emeršič A, Vrillon A, et al. . Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer’s disease diagnosis. Alzheimers Dement. 2021;17:755–767.
- Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–259.
- Mirra SS, Heyman A, McKeel D, et al. . The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41:479–479.
- Montine TJ, Phelps CH, Beach TG, et al. . National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: A practical approach. Acta Neuropathol. 2012;123:1–11.
- Hyman BT, Trojanowski JQ. Editorial on consensus recommendations for the postmortem diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095–1097.
- Smirnov DS, Ashton NJ, Blennow K, et al. . Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143:487–503.
- Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.
- Höglinger GU, Respondek G, Stamelou M, et al. . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32:853–864.
- Armstrong MJ, Litvan I, Lang AE, et al. . Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.
- McKhann GM, Knopman DS, Chertkow H, et al. . The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the national institute on aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269.
- Benussi A, Karikari TK, Ashton N, et al. . Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91:960–967.
- Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. . A practical guide to immunoassay method validation. Front Neurol. 2015;6:179.
- Saracino D, Dorgham K, Camuzat A, et al. . Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: From tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;92:1278–1288.
- Hesse C, Rosengren L, Andreasen N, et al. . Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett. 2001;297:187–190.
- Feinstein I, Wilson EN, Swarovski MS, Andreasson KI, Angst MS, Greicius MD. Plasma biomarkers of tau and neurodegeneration during major cardiac and noncardiac surgery. JAMA Neurol. 2021;78:1407.
- Bulut M, Koksal O, Dogan S, et al. . Tau protein as a serum marker of brain damage in mild traumatic brain injury: Preliminary results. Adv Ther. 2006;23:12–22.
- Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159–168.
- Georgieff IS, Liem RK, Couchie D, Mavilia C, Nunez J, Shelanski ML. Expression of high molecular weight tau in the central and peripheral nervous systems. J Cell Sci. 1993;105:729–737.
- Hansson O, Janelidze S, Hall S, et al. . Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017;88:930–937.
- Chong JR, Ashton NJ, Karikari TK, et al. . Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer’s disease: A focused review on recent advances. J Neurol Neurosurg Psychiatry. 2021;92:1231–1241.
- Karikari TK, Benedet AL, Ashton NJ, et al. . Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429–442.
- Alcolea D, Delaby C, Muñoz L, et al. . Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. J Neurol Neurosurg Psychiatry. 2021;92:1206–1214.
Source: PubMed